Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 70 results for "Tecfidera Treated Patients"

Biogen more than halves 2015 outlook guidance as Q2 sales disappoint; shares plummet
Proactive Investors USA

Biogen more than halves 2015 outlook guidance as Q2 sales disa...

2:11 pm by A patient's death on Tecfidera, reported last year, may have alarmed doctors and patients and slowed the drug's growth, Tony Kingsley, Biogen's head of global commercial operations, said on a call with investors. Biogen () tumbled ... Proactive Investors USA, 1 month ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 3, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Rege…

Several major biotech companies like Biogen ( BIIB - Analyst Report ), AbbVie ( ABBV - Analyst Report ), Celgene and Gilead reported second quarter results over the last five trading days. Biogen has been grabbing headlines for the wrong reasons ...
 Zacks.com1 month ago

Regulus snags milestone in MS biomarker deal with Biogen

Regulus Therapeutics ($RGLS) has partnered up with Biogen Idec ($BIIB) to identify microRNA biomarkers in the blood of patients with multiple sclerosis. The California biotech has charted some progress, pocketing a milestone payment and moving ...
 Fierce BioMarkers1 month ago

Biogen (BIIB) Reports Second Non-Fatal Tecfidera PML Case 7/20/2015

July 17, 2015 By Mark Terry , Breaking News Staff Cambridge, Mass.-based Biogen, Inc. reported yesterday that a second patient taking the company's multiple sclerosis drug Tecfidera (dimethyl fumarate) has developed a ...
 ClinicSpace1 month ago Biogen Falls Hard: Is It Undervalued Now?  Seeking Alpha1 month ago Why All Eyes Will Be on Biogen (BIIB)'s Alzheimer's Data Next Week 7/16/2015  ClinicSpace1 month ago Genentech (RHHBY)'s Ocrelizumab Wows in Late Stages and Eyes $18 Billion MS Market 7/1/2015  ClinicSpace2 months ago
Jutia Group

Company Update: Biogen Idec Inc (NASDAQ:BIIB) Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B

[Business Wire] DALLAS(BUSINESSWIRE) New clinical data support the long-term safety and efficacy of ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in people with severe hemophilia B treated for up to two years, Biogen ...
 Jutia Group2 weeks ago Market Update: Biogen Idec Inc (NASDAQ:BIIB) Biogen, the ALS Association and Columbia University Medical Center Collaborate to Drive Understanding of Genetic Influence in ALS  Jutia Group2 weeks ago Stock Update: Biogen Idec Inc (NASDAQ:BIIB) BIIB INVESTORS: The Law Offices of Howard G. Smith Announces An Investigation On Behalf Of Biogen, Inc. Investors  Jutia Group1 month ago Attention New Biotech Investors: Biogen Inc's Recent Weakness Is Your Opportunity  Motley Fool1 month ago
Motley Fool

The Blockbuster Potential of Biogen Inc's Pipeline

Blue chip biotech stock Biogen ( NASDAQ:BIIB ) has fallen out of Wall Street's good graces recently after reporting slowing sales growth of its multiple sclerosis drug Tecfidera. While that might prove to be a short-term headwind that hampers top ...
 Motley Fool1 month ago Biogen Inc (BIIB) Stock Soars On Bank Of America's Upgrade To Buy  Bidness Etc1 month ago

ALKERMES PLC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our condensed consolidated financial statements and related notes beginning on page 5 of this Form 10-Q, and Management's Discussion and Analysis of Financial Condition and Results of ...
 Pharmacy Choice1 month ago

Alkermes' (ALKS) CEO Richard Pops on Q2 2015 Results - Earnings Call Transcript

Operator Ladies and gentlemen, thank you for standing by and welcome to the Alkermes Conference Call to discuss the company's Second Quarter Financial Results. At this time, all participants are in a listen-only mode. There will be a ...
 Seeking Alpha1 month ago Biogen (BIIB) George A. Scangos, Ph.D. on Q2 2015 Results - Earnings Call Transcript  Seeking Alpha1 month ago

The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases

For Immediate Release Chicago, IL July 30, 2015 announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
 Yahoo! Finance1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less